TIDMAREC

RNS Number : 3465M

Arecor Therapeutics PLC

23 May 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

AGM STATEMENT

Building on strong foundations to deliver a transformational year

Cambridge, UK, 23 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, provides the following update ahead of its Annual General Meeting, held today at 1.00 pm at the offices of Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ.

At the meeting, Andrew Richards, Non-Executive Chair, will make the following statement:

"2021 was a truly transformational year for Arecor and the Company has continued to make huge strides to continue this trajectory of growth. During the year, our pipeline of proprietary and partnered products received validation through both exceptional clinical data and partnership progress. It is our vision to create a sustainable biopharmaceutical company, by rejuvenating existing therapeutic products to make them better, safer and more convenient to use.

Our two lead clinical stage programmes are focused on improving the lives of those living with diabetes. The impact that the growing global number of diabetes patients is having on our resources, health sector and lives cannot be underestimated. The Phase I clinical trial data for both our lead product, AT247, an ultra-rapid insulin and for our second product AT278, a concentrated rapid insulin targeting patients who require higher volumes of insulin, excelled our expectations. We believe that our products will provide that key to unlock the future treatment landscape for diabetes.

With our partnered portfolio continuing to attractive high calibre pharmaceutical companies and strong support from our shareholders following our successful IPO on the London Stock Exchange last year, we believe that Arecor is well positioned to both deliver on existing programmes and attract new and exciting opportunities in the coming year to create long-term shareholder value."

Further information about the AGM can be found in the investor centre section of our website https://arecor.com/investor-centre/shareholder-information/. To register for the webinar, click here.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer     Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Mo Noonan, Communications                  Tel: +44 (0) 7876 444977 
                                             Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: +44 (0) 20 3709 5700 
  Gray                                       Email: arecor@consilium-comms.com 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMATMRTMTTTBLT

(END) Dow Jones Newswires

May 23, 2022 02:00 ET (06:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Arecor Therapeutics Charts.